Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Tension Helps Heart Cells Develop Normally in the Lab
Stanford engineers have uncovered the important role tension plays in growing heart cells out of the body.
Controlling Body Temperature in Response to 'Fight or Flight'
New research in The FASEB Journal suggests that blocking TRPV1 protein causes an increased release of noradrenaline, leading to an increase in core body temperatures.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Scroll Up
Scroll Down

Five Keys to Reducing Time-to-Market
Bookmark and Share

Vetter Pharma International GmbH

With development times measured in years, increasing costs represent a major challenge confronting pharmaceutical and biotechnology companies. As a result, reducing time-to-market is an essential component in any business strategy, particularly when the end of patent protection is considered. One solution is to partner with a contract manufacturer that provides intelligent concepts and the proper experience, not only with respect to the production itself, but also with regulatory authorities. Planning early on is crucial to speeding up the time-to-market process.

According to Benjamin Franklin’s famous quote in Poor Richard’s Almanac, “Time is money”. The American hero of the revolution, scientist and sage illustrated his point with an example involving ten shillings and six pence. Had Franklin been writing about today’s pharmaceutical industry, he might have been tempted to underscore his advice to do justice to the substantial sums involved – up to $1 million daily in the later stages of developing a new drug.

Further Information

Related Content

Vetter’s Newest Facility Successfully Completes FDA Inspection
Center for visual inspection and logistics sets high safety and control standards.
Thursday, March 28, 2013

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos